Corporate ActionJun 26, 2026, 07:01 AM
Avalo Therapeutics to Join Russell 2000 & 3000 Indexes
AI Summary
Avalo Therapeutics, Inc. announced its upcoming inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This change will be effective after the close of U.S. equity markets on June 26, 2026. The company, a clinical stage biotechnology firm, develops therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead asset abdakibart recently showing positive Phase 2 data.
Key Highlights
- Avalo Therapeutics to be added to the Russell 2000® Index.
- Avalo Therapeutics to be added to the Russell 3000® Index.
- Inclusion in both indexes is effective after market close on June 26, 2026.
- The Russell 2000® Index is a leading benchmark for U.S. small-cap equities.
- The Russell 3000® Index measures the performance of the largest 3,000 U.S. companies.
- Avalo Therapeutics is a clinical stage biotechnology company focused on the IL-1β pathway.
- Lead asset abdakibart recently reported positive Phase 2 data in hidradenitis suppurativa (HS).
Price Impact
More from AVTX